624734-22-1

Basic information

• Product Name: 2-Chloro-5-trifluoromethyl-nicotinonitrile
• Synonyms: 2-Chloro-5-trifluoromethyl-nicotinonitrile;2-chloro-5-(trifluoroMethyl)pyridine-3-carbonitrile;2-chloro-3-cyano-5-trifluoroMethylpyridine;2-chloro-5-(trifluoromethyl)-3-Pyridinecarbonitrile
• CAS NO: 624734-22-1
• Molecular Formula: C₇H₂ClF₃N₂
• Molecular Weight: 206.55
• Mol File: 624734-22-1.mol

Chemical Properties

• Boiling Point: 251.6±35.0 °C(Predicted)
• Appearance: /
• Density: 1.51±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.88±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-5-trifluoromethyl-nicotinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-trifluoromethyl-nicotinonitrile(624734-22-1)
• EPA Substance Registry System: 2-Chloro-5-trifluoromethyl-nicotinonitrile(624734-22-1)

Safety Data

• Hazardous Substances Data: 624734-22-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-trifluoromethyl-nicotinonitrile is used as a chemical intermediate for the synthesis of pharmaceutical compounds due to its reactivity and ability to inhibit specific enzymes and receptors. This makes it a key component in the development of new drugs that target these biological entities.
Used in Medication Development:
As a potent inhibitor, 2-Chloro-5-trifluoromethyl-nicotinonitrile is utilized in the creation of medications that require specific enzyme or receptor inhibition for their therapeutic effects. Its role in this process is crucial for the advancement of certain treatments.
Used in Research and Development:
In the field of research and development, 2-Chloro-5-trifluoromethyl-nicotinonitrile serves as a valuable tool for studying the mechanisms of enzyme and receptor interactions. This helps in understanding disease pathways and developing targeted therapies.
Used in Environmental and Safety Protocols:
Due to its toxic nature, 2-Chloro-5-trifluoromethyl-nicotinonitrile is also used in the development of safety protocols and environmental guidelines for its handling, storage, and disposal. This ensures the protection of both human health and the environment from potential hazards associated with 2-Chloro-5-trifluoromethyl-nicotinonitrile.

Upstream product

• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 
• 76041-73-1 3-bromo-5-(trifluoromethyl)pyridin-2-ol 
• 129904-48-9 2-hydroxy-5-(trifluoromethyl)nicotinaldehyde 
• 505084-59-3 2-chloro-5-(trifluoromethyl)pyridine-3-carboxylic acid 
• 1279217-36-5 2-chloro-5-(trifluoromethyl)pyridine-3-carboxamide 
• 52334-81-3 2-chloro-5-trifluoromethylpyridine 
• 1099597-75-7 2-chloro-5-(trifluoromethyl)pyridine-3-carbonyl chloride 

Downstream Products

• 624734-27-6 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 624734-26-5 tert-butyl 3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 
• 124432-68-4 2-methoxy-5-(trifluoromethyl)nicotinonitrile 
• 766513-53-5 [5-(trifluoromethyl)-3-pyridyl]methanamine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS

The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting growing plants and

COMPOUNDS AND USE THEREOF IN THE EXPANSION OF STEM CELLS AND/OR PROGENITOR CELLS

The invention relates to compounds of formula I and pharmaceutical compositions containing them. Also, the invention relates to methods for expanding stem cells and/or progenitor cells and methods for treating a hematopoietic disorder/malignancy, and autoimmune disease and/or an inherited immunodeficient disease (I).

PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF

Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza.

CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

2,6-Disubstituted piperiddines as modulators

The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

ALKYLAMINO, ARYLAMINO, AND SULFONAMIDO CYCLOPENTYL AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of the formula (I) which are modulators of chemokine receptor activity useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

AMINO HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II: (wherein n, R 1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33 R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

3,3-DISUBSTITUTED TETRAHYDROPYRANYL CYCLOPENTYL AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and im

3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors

The present invention is directed to compounds of Formula I: which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or act